The state of Arkansas currently has 3 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. These trials are conducted in various cities, including Little Rock, Jonesboro, Hot Springs and Fayetteville.
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1 or type 2 (HAE-1/2), a proportion of whom are using long-term prophylactic medication for HAE.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
01/28/2025
Locations: Study Site, Little Rock, Arkansas
Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/06/2025
Locations: KalVista Investigative Site, Little Rock, Arkansas
Conditions: Hereditary Angioedema
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Recruiting
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas
Conditions: Hereditary Angioedema